Last reviewed · How we verify
Kenacort®
At a glance
| Generic name | Kenacort® |
|---|---|
| Sponsor | Holger Joswig |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Urinary tract infection
- Constipation
- Grades 3-5 Cardiac Disorders
- Wound complication
- Hyperkalaemia
- Oedema peripheral
- Grades 3-5 GI Disorders
- Diarrhoea infectious
- Hypertension
- Grades 3-5 General Disorders
- Nausea
- BK virus infection
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus (PHASE2)
- Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata (NA)
- Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. (PHASE3)
- Does it Matter the Volume of Injectate on the Outcome of Ultrasound-guided Perineural Injection for Carpal Tunnel Syndrome (PHASE4)
- Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PHASE4)
- Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer (PHASE2)
- Oxygenated Gel Therapy in the Management of Oral Aphthous Ulcers (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kenacort® CI brief — competitive landscape report
- Kenacort® updates RSS · CI watch RSS
- Holger Joswig portfolio CI